VEGF121b, a new member of the VEGF xxx b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo

VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy

(2008) A H R Varey et al.   BRITISH JOURNAL OF CANCER

The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice

(2008) E S Rennel et al.   BRITISH JOURNAL OF CANCER

Vascular Endothelial Growth Factor (VEGF)-A165b Is a Weak In vitro Agonist for VEGF Receptor-2 Due to Lack of Coreceptor Binding and Deficient Regulation of Kinase Activity

(2008) H. Kawamura et al.   CANCER RESEARCH

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice

(2008) Emma S. Rennel et al.   EUROPEAN JOURNAL OF CANCER

Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR

(2008) Stéphanie Cébe-Suarez et al.   FASEB JOURNAL

Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors

(2008) D. G. Nowak et al.   JOURNAL OF CELL SCIENCE

Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b

(2007) Yan Qiu et al.   FASEB JOURNAL